Results 151 to 160 of about 54,010 (241)

Enzymatic Laccase Nanoreactors Induce Apoptosis in MOLT-4-ALL Cells and Activate Prodrugs in a Synergetic Effect. [PDF]

Blood Lymphat Cancer
Medrano-Villagómez CA, Loredo-García E, Gasperin-Bulbarela J, Vazquez-Duhalt R.   +3 more
europepmc   +1 more source

FASN Inhibition Enhances the Efficacy of Chemotherapy in Colorectal Cancer by Inhibiting the DNA Damage Response. [PDF]

Cancer Res
Banerjee M, Zaytseva YY, Reusch EM, Napier DL, Hasani S, Rychahou P, Izumi T, Cheek DA, Li J, Flight RM, Moseley HNB, Weiss HL, McCulloch W, Evers BM, Gao T.   +14 more
europepmc   +1 more source

Phase I trial of zalutumumab and irinotecan in metastatic colorectal cancer patients who have failed irinotecan- and cetuximab-based therapy

, 2009
[Background:] Zalutumumab is a novel human IgG1 anti-EGFR mAb. We investigated the safety of zalutumumab and irinotecan in heavily pretreated mCRC patients.
Hendlisz, Alain, Ehrnrooth, E., 45th Annual Meeting of the American-Society-of-Clinical-Oncology, Van Laethem, Jean-Luc, Aladdin, H., Machiels, Jean-Pascal, Mano, Max S.   +6 more
core  

Association Between Irinotecan-Containing Regimens and Functional and Nutritional Impairment in Advanced Colorectal Cancer: An Exploratory PG-SGA Analysis. [PDF]

Cancers (Basel)
Guerrero-Martín J, Macias-Montero R, Macías-Gañán Y, Araujo-Blesa M, Paniagua-Vivas MS, Sánchez-Diestro LE.   +5 more
europepmc   +1 more source

Distinct safety profiles of liposomal and conventional irinotecan: insights from clinical experience and real-world data. [PDF]

Front Pharmacol
Shan H, Huang S, Du Q, Wang M.
europepmc   +1 more source

The Synthesis of (S)-Camptothecin and Clinically Useful Analogs

, 2003
A six-step synthesis of (S)-camptothecin (CPT) was completed relinquishing a fast, efficient route to this natural product. The key steps included the formation of the 4-iodo-2,3-pyridylacetal intermediate 56 required to obtain the DE ring moiety of CPT,
Nolan, Jason Michael
core  

Elucidating the Solvent-Dependent Solvation and Structural Stability of Irinotecan: A Molecular Simulation Study. [PDF]

Chemphyschem
Bitabo MM, Mlowe S, Shadrack DM, Paluch AS, Paul L.   +4 more
europepmc   +1 more source

Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer model. [PDF]

Front Oncol
Lentz RW, Dominguez ATA, Balmaceda NB, Arcaroli JJ, Bagby SM, Binns CA, Smoots SG, Jackson MM, Macbeth M, Holmstoen T, Banerjee T, Whitty PA, Yi SS, Lieu CH, Messersmith WA, Pitts TM.   +15 more
europepmc   +1 more source

Safety and Efficacy of FOLFIRI-3 (Split-Dose Irinotecan) for Unresectable Colorectal Cancer: A Stratified Analysis Based on <i>UGT1A1</i> Gene Polymorphisms. [PDF]

Cancers (Basel)
Ohira G, Miyauchi H, Tochigi T, Maruyama T, Okada K, Hirata A, Ikeda Y, Hayano K, Maruyama M, Ishige T, Matsushita K, Shuto K.   +11 more
europepmc   +1 more source

Irinotecan with trifluridine/tipiracil and bevacizumab for second-line metastatic colorectal cancer: a phase II multicenter study. [PDF]

Signal Transduct Target Ther
Yang W, Zhang J, Liang P, Qian Z, Wang D, Zhang W, Li B, Cui C, Zhong X, Wu G, Sun Y.   +10 more
europepmc   +1 more source